Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma

References

• Townsend W, Linch D. Hodgkin’s lymphoma in adults. Lancet. 2012;380(9844):836–847. doi:10.1016/S0140-6736(12)60035-X
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. doi:10.3322/caac.21438
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072. doi: 10.1016/j.bbmt.2006.06.006
   PubMed Web of Science ®Google Scholar
• Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997;3(2):98–106.
   PubMedGoogle Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623. doi: 10.1182/blood.V97.3.616
   PubMed Web of Science ®Google Scholar
• Nademanee A, O’Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995;85(5):1381–1390.
   PubMed Web of Science ®Google Scholar
• Hurd DD, Haake RJ, Lasky LC, et al. Treatment of refractory and relapsed Hodgkin’s disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Med Pediatr Oncol. 1990;18(6):447–453. doi: 10.1002/mpo.2950180603
   PubMedGoogle Scholar
• Burns LJ, Daniels KA, McGlave PB, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin’s disease: factors predictive of prolonged survival. Bone Marrow Transplant. 1995;16(1):13–18.
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169
   PubMed Web of Science ®Google Scholar
• Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440–1449. doi: 10.1038/nm1676
   PubMed Web of Science ®Google Scholar
• Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra153. doi: 10.1126/scitranslmed.3003761
   Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267–276. doi:10.1038/nrclinonc.2013.46
   PubMed Web of Science ®Google Scholar
• He X, Feng Z, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713–723. doi: 10.1182/blood.2019002779
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591). doi: 10.1126/scitranslmed.abe7378
   Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-beta receptor enhances PSMA-Targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–1866. doi: 10.1016/j.ymthe.2018.05.003
   PubMed Web of Science ®Google Scholar
• Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539–551. doi:10.1016/j.apsb.2018.03.001
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711
   PubMed Web of Science ®Google Scholar
• Chang ZL, Chen YY. Cars: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430–450. doi:10.1016/j.molmed.2017.03.002
   PubMed Web of Science ®Google Scholar
• Enblad G, Karlsson H, Loskog AS. CAR T-Cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther. 2015;26(8):498–505. doi:10.1089/hum.2015.054
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494–502. doi:10.1016/j.it.2015.06.004
   PubMed Web of Science ®Google Scholar
• Advani A. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2015;28(2–3):116–123. doi:10.1016/j.beha.2015.10.008
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. Trucks: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430
   PubMed Web of Science ®Google Scholar
• Benmebarek MR, Karches CH, Cadilha BL, et al. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20(6):1283. doi: 10.3390/ijms20061283
   PubMed Web of Science ®Google Scholar
• Meiraz A, Garber OG, Harari S, et al. Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo. Immunology. 2009;128(1):69–82. doi:10.1111/j.1365-2567.2009.03072.x
   PubMed Web of Science ®Google Scholar
• Stinchcombe JC, Majorovits E, Bossi G, et al. Centrosome polarization delivers secretory granules to the immunological synapse. Nature. 2006;443(7110):462–465. doi:10.1038/nature05071
   PubMed Web of Science ®Google Scholar
• Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):203. doi:10.1186/s12885-019-5415-9
   PubMedGoogle Scholar
• Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–427. doi:10.1016/0092-8674(92)90180-K
   PubMed Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848–858. doi: 10.1182/blood.V66.4.848.848
   PubMed Web of Science ®Google Scholar
• Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–158. doi:10.1007/s12026-013-8464-1
   PubMed Web of Science ®Google Scholar
• Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–67. doi: 10.1038/299065a0
   PubMed Web of Science ®Google Scholar
• Gerdes J, Schwarting R, Stein H. High proliferative activity of Reed Sternberg associated antigen ki-1 positive cells in normal lymphoid tissue. J Clin Pathol. 1986;39(9):993–997. doi:10.1136/jcp.39.9.993
   PubMed Web of Science ®Google Scholar
• Ralfkiaer E, Bosq J, Gatter KC, et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res. 1987;279(5):285–292. doi: 10.1007/BF00431219
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin’s lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58(6):1116–1119.
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–126. doi:10.1111/imr.12131
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620–2630. doi: 10.1182/blood-2006-11-059139
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13. doi: 10.1016/S0140-6736(95)91150-2
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–1555. doi: 10.1182/blood.V92.5.1549.417k32_1549_1555
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–383. doi:10.1038/nrclinonc.2016.36
   PubMed Web of Science ®Google Scholar
• Hombach AA, Abken H. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells? Expert Rev Clin Immunol. 2017;13(2):151–155. doi:10.1080/1744666X.2016.1221763
   PubMed Web of Science ®Google Scholar
• Hombach AA, Gorgens A, Chmielewski M, et al. Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol Ther. 2016;24(8):1423–1434. doi: 10.1038/mt.2016.82
   PubMed Web of Science ®Google Scholar
• Lynn RC, Poussin M, Kalota A, et al. Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood. 2015;125(22):3466–3476. doi: 10.1182/blood-2014-11-612721
   PubMed Web of Science ®Google Scholar
• Lynn RC, Feng Y, Schutsky K, et al. High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30(6):1355–1364. doi: 10.1038/leu.2016.35
   PubMed Web of Science ®Google Scholar
• Wang CM, Wu ZQ, Wang Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin Lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156–1166. doi: 10.1158/1078-0432.CCR-16-1365
   PubMed Web of Science ®Google Scholar
• Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462–3471. doi: 10.1172/JCI94306
   PubMed Web of Science ®Google Scholar
• Sang W, Wang X, Geng H, et al. Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma. Front Immunol. 2022;13:858021. doi: 10.3389/fimmu.2022.858021
   PubMed Web of Science ®Google Scholar
• Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin Lymphoma. J Clin Oncol. 2020;38(32):3794–3804. doi: 10.1200/JCO.20.01342
   PubMed Web of Science ®Google Scholar
• Voorhees TJ, Zhao B, Oldan J, et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022;6(4):1255–1263. doi: 10.1182/bloodadvances.2021005385
   PubMed Web of Science ®Google Scholar
• Voorhees TJ, Grover NS, Beaven A, et al. Retrospective cohort study analyzing the safety and efficacy of anti-PD-1 therapy following CD30 CAR-T cell therapy in relapsed/refractory Hodgkin Lymphoma. Blood. 2019;134(Supplement_1):3233–3233. doi: 10.1182/blood-2019-122846
   Google Scholar
• Xue Y, Lai X, Li R, et al. CD19 and CD30 CAR T-Cell immunotherapy for high-risk classical Hodgkin’s lymphoma. Front Oncol. 2020;10:607362. doi: 10.3389/fonc.2020.607362
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392–6402. doi: 10.1182/blood-2009-03-209650
   PubMed Web of Science ®Google Scholar
• Guercio M, Orlando D, Di Cecca S, et al. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. Haematologica. 2021;106(4):987–999. doi: 10.3324/haematol.2019.231183
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750–3759. doi: 10.1182/blood-2014-01-552174
   PubMed Web of Science ®Google Scholar
• Guo J, He S, Zhu Y, et al. Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells. Front Cell Dev Biol. 2021;9:775599. doi:10.3389/fcell.2021.775599
   PubMed Web of Science ®Google Scholar
• Choi S, Pegues MA, Lam N, et al. Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains. Hum Gene Ther. 2021;32(13–14):730–743. doi:10.1089/hum.2020.215
   PubMed Web of Science ®Google Scholar
• Fu W, Lei C, Liu S, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10(1):4355. doi: 10.1038/s41467-019-12321-3
   PubMed Web of Science ®Google Scholar